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Abstract
Background—The Patient Reported Outcomes Measurement Information System (PROMIS) II 
is a prospective study that evaluates patient reported outcomes in pediatric chronic diseases as a 
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measure of health-related quality of life (HRQOL). We have evaluated the influence of disease 
duration on HRQOL and, for the first time, compared the findings of the PROMIS measures to 
those of the PedsQL™ 4.0 Generic Scales (PedsQL) from the PROMIS II nephrotic syndrome 
(NS) longitudinal cohort.
Methods—This was a prospective study in which 127 children (age range 8–17 years) with 
active NS from 14 centers were enrolled. Children with active NS defined as the presence of 
nephrotic range proteinuria (>2+ urinalysis and edema or urine protein/creatinine ratio >2 g/g) 
were eligible. Comparisons were made between children with prevalent (N=67) and incident 
(N=60) disease at the study enrollment visit.
Results—The PROMIS scores were worse in prevalent patients in the domains of peer 
relationship (p=0.01) and pain interference (p < 0.01). The PedsQL showed worse scores in 
prevalent patients for social functioning (p < 0.01) and school functioning (p = 0.03). 
Multivariable analyses showed that prevalent patients had worse scores in PROMIS pain 
interference (p=0.02) and PedsQL social functioning (p<0.01).
Conclusion—The PROMIS measures detected a significant impact of disease duration on 
HRQOL in children, such that peer relationships were worse and pain interfered with daily life to 
a greater degree among those with longer disease duration. These findings were in agreement with 
those for similar domains in the PedsQL legacy instrument.
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Patient-reported outcomes; Quality of life; Nephrotic syndrome; Pediatrics; Children
Introduction
Nephrotic syndrome (NS) is a challenging relapsing and remitting disease typified by a 
spectrum of disease trajectories, ranging from a single episode, infrequently relapsing, 
frequently relapsing, to persistent progressive disease [1]. In the worst cases, the disease 
course in children can result in multiple complications, frequent hospitalizations, and end-
stage kidney disease. Frequently, the disease process spans a significant portion of the 
formative years of a child’s life and can extend into adulthood. As a result, the 
comprehensive care of children with NS may benefit by the formal assessments of the 
impact of disease on the physical and psychosocial aspects of health-related quality of life 
(HRQOL). A better understanding of the HRQOL in children with NS can assist in 
understanding how children feel and function to better guide clinical care.
Disease characteristics inherent to NS including edema, repeated corticosteroid exposures, 
and the relapsing nature of the disease pose challenges to patients’ HRQOL [2, 3]. Recent 
studies in children on the impact of NS on HRQOL have shown impairments in physical, 
social, and emotional functioning [2–4]. Gipson et al. recently reported the initial validation 
of the Patient Reported Outcomes Measurement Information System® (PROMIS®) 
pediatric measures (grant U01AR052181) in children with NS. The PROMIS measures were 
responsive to disease status, with worse HRQOL in the domains of anxiety, fatigue, pain 
interference, and mobility in children with active NS [3]. To date these studies have 
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investigated elements inherent to the disease that influence HRQOL, but have not 
investigated the influence of disease duration on HRQOL.
For those seeking to evaluate HRQOL in children with chronic diseases, the PROMIS and 
PedsQL™ 4.0 Generic Core Scales (PedsQL) represent two tools available to both the 
researcher and the clinician. The PROMIS measures were created through a National 
Institutes of Health initiative to improve the assessment of HRQOL [5]. In the first phase of 
PROMIS, nine “item banks” were developed for the measurement of self-reported outcomes 
in children aged 8–17 years: depression, anxiety, anger, social-peer relationships, pain 
interference, fatigue, mobility, upper extremity functioning, and asthma impact [6–11]. An 
item bank is a library of items that have gone through extensive qualitative and quantitative 
evaluation to ensure reliable and valid representations of the HRQOL domain they are 
measuring (e.g., fatigue). The measurement properties of each item in the PROMIS item 
banks were calibrated with item response theory (IRT) models to determine an item’s 
discrimination ability and the level (or severity) of the HRQOL construct the item is 
measuring. Thus, PROMIS is very different from patient-reported outcome (PRO) measures 
such as the PedsQL or the Short Form (36) Health Survey (SF-36) in that it allows 
investigators to tailor PRO measures to an individual or group by selecting items in the item 
bank which are relevant for their population [5]. With PROMIS, investigators have a great 
deal of control and can select the HRQOL domains they want to measure, determine if the 
system will administer individually tailored questionnaires (i.e., computerized adaptive 
testing) or fixed item short forms, and select the length of the questionnaire. The PROMIS 
measures have been validated in a number of childhood chronic illnesses, including cancer, 
asthma, obesity, chronic kidney disease, and NS, in cross-sectional studies [3, 12–14]. In 
comparison, the PedsQL is a well-used legacy instrument that was developed utilizing 
classical test theory and which assesses physical, emotional, social, and school functioning 
[15–18]. To date, the information provided by the PROMIS and PedsQL instruments has not 
been compared in the setting of pediatric NS.
PROMIS II was designed as a follow-up study to the initial validation of the pediatric 
PROMIS instrument that seeks to evaluate change in HRQOL longitudinally in children 
with a number of chronic diseases, including those with NS (prevalent or incident). The 
current study focuses on the baseline HRQOL data from the PROMIS II NS cohort at the 
initial assessment. The goal of our analysis was to compare the differences in HRQOL in 
children with prevalent versus incident NS to investigate the impact of disease duration on 
HRQOL as measured by the PROMIS measures. A secondary aim of this study was to 
compare the consistency of the findings of the PROMIS and the PedsQL instruments. We 
hypothesized that children with longer disease duration would have increased symptom 
burden and worse HRQOL. Furthermore, we hypothesized that the PROMIS and PedsQL 
instruments would provide complementary information on the impact of NS disease on the 
children’s HRQOL.
Methods
The children enrolled in the PROMIS II NS longitudinal cohort study had active NS and 
were being treated at one of the 14 participating centers (12 from the Midwest Pediatric 
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Nephrology Consortium and 2 other centers in the USA). Each participating center obtained 
Institutional Review Board approval. Parents and children gave informed consent and 
assent, respectively.
Consistent with the target age for the PROMIS pediatric measures, the PROMIS II NS 
cohort included children aged 8–17 years. Children with active NS, defined as the presence 
of nephrotic range proteinuria [>2+ urinalysis and edema or urine protein/creatinine (UPC) 
ratio >2 g/g] were eligible for entry. Exclusion criteria included co-existing medical, 
psychiatric, or cognitive impairments that would prevent the patient from answering the 
computer-administered questionnaire, the inability to speak and read English, or kidney 
failure defined as dependence on dialysis or kidney transplant.
The longitudinal study included three assessments. In the current study, we evaluated data 
from the assessments at the enrollment visit. The child completed the PROMIS and the 
PedsQL™ 4.0 Generic Core Scale measures (parent proxy measures were not measured in 
this study). The parent completed the Family and Medical Information form, which included 
information on his/her relationship to the child, guardian education level, socioeconomic 
data, and disease-specific questions. Demographic data and data on disease characteristics 
were collected for each child (Table 1). Children were asked to describe their symptoms in 
the previous 7 days (Table 2). Children at their initial presentation and with <14 days of 
therapy before enrollment were defined as having “incident” disease; the remaining patients 
were classified as having “prevalent” disease. For the sub-class analysis, the prevalent 
patients were then classified as into those with infrequently relapsing steroid-responsive 
disease, frequently relapsing steroid-responsive disease, steroid-dependent disease, and 
steroid-resistant disease [1]. Children that were never edematous were classified as never 
relapsed. The glomerular filtration rate (GFR) was estimated by the new Chronic Kidney 
Disease in Children (CKiD) equation [19].
The PROMIS pediatric measures include the domains of depression, anxiety, social-peer 
relationships, pain interference, fatigue, and mobility. We used the PROMIS Assessment 
Center web-based interface (www.assessmentcenter.net) to administer the questionnaires. 
Each PROMIS question used the context statement “In the past 7 days.” Responses included 
five options ranging from “never” to “almost always” in the majority of domains, and from 
“with no trouble” to “not able to do” for the physical functioning measures (Electronic 
Supplementary Material 1). Each PROMIS pediatric measure generates a t score relative to a 
mean of 50 and a standard deviation (SD) of 10 in the original PROMIS-I calibration 
population that included both children with disease and healthy children [6]. Higher scores 
indicate higher levels of the domain consistent with the measure’s name, thus signifying 
worse symptoms of depression, anxiety, fatigue, and pain interference and better functioning 
for mobility and peer relationships. The PROMIS instrument is designed for children to be 
able to answer five questions per minute. The PROMIS pediatric measures have not been 
validated in healthy children, but such a study is currently underway.
The PedsQL is a legacy instrument designed to measure HRQOL in children. The 
instrument measures physical, emotional, social, school, and overall functioning. This 
instrument has been evaluated in healthy children and in multiple pediatric chronic 
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conditions including chronic kidney disease [17]. The PedsQL asks subjects to review 
statements and rate the degree that the subject has experienced that symptom in the past 
week. The domain scores result from the summation of problem frequency within each 
domain. Higher scores indicate better function, with a range of 0–100 and a SD of 15. The 
PedsQL instrument is designed for children to be able to complete the instrument in 10 min.
Statistical considerations
Descriptive statistics on key variables of interest were provided via proportions and means 
for the full cohort and by eligibility type. Medians were provided for non-normally 
distributed continuous variables. PedsQL scores were compared to a normative sample using 
independent sample t tests [18]. This was done separately for the full sample and for patients 
with incident and prevalent disease, respectively. The main outcome variables of interest 
were the 11 HRQOL measures. We began with a series of bivariate linear regression models 
for each outcome using the following covariates: sex, age, race, Hispanic ethnicity, obesity 
(body mass index>95th percentile), edema, number of symptoms, estimated (e)GFR [19], 
UPC ratio, serum albumin, hospitalization in the past 6 months, emergency room visit in the 
past 6 months, number of medications, and disease duration coded as incident versus 
prevalent. For each outcome, any factor that was a significant predictor at α=0.25 was 
included for multivariable backward selection steps. Variables were eliminated from the 
models in order of descending p value until all remaining variables were significant at 
α=0.05. Finally, we conducted two simultaneous multivariable linear regressions for 
PROMIS and PedsQL separately, where each covariate was simultaneously regressed on the 
six PROMIS domains and the four primary PedsQL domains. The same set of covariates 
was used in the backwards selection in Table 4 to achieve simpler models for better 
interpretation. Joint tests of significance for a covariate on all domains were performed 
using Wilks’ Lambda statistic, which mitigates the inherent problem of multiple 
comparisons in the analysis of several separate outcomes. In a separate sensitivity analysis, 
we estimated the effect that steroid response pattern (infrequently relapsing steroid 
responsive, frequently relapsing steroid responsive, steroid dependent, steroid resistant, vs. 
never relapsed) had on PRO measures among prevalent patients.
We also explored the degree to which the PROMIS and PedsQL domains correlate with one 
another using Pearson correlation coefficients, with the expectation that similar domains 
across instruments (e.g., PROMIS: Mobility; PedsQL: Physical Functioning) would show a 
reasonable amount of correlation.
Results
Child demographic and disease characteristics are presented in Table 1. There were 127 
children enrolled and included in the analysis. The study population included 60 and 67 
patients with incident and prevalent NS, respectively. The median duration of disease for 
incident patients was 4 [interquartile range (IQR) 0, 11] days with a maximum of 31 days. 
Children with prevalent disease had a median disease duration of 73 (IQR 35, 126) months 
prior to enrollment. All prevalent patients had disease duration of >2 months, and 75 % had 
disease duration of >2 years. The disease characteristics of patients with prevalent NS 
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included: infrequently relapsing steroid-responsive disease (N=9), frequently relapsing 
steroid-responsive disease (N=17), steroid-dependent disease (N=24), steroid-resistant 
disease (N=9), never relapsed (N= 1), and unknown (N=7). Table 2 describes the patient-
reported symptoms experienced by children. There were no significant differences in the 
types of symptoms reported between incident and prevalent patients, but patients with 
prevalent disease had more symptoms (p=0.04). There was no difference in the number of 
symptoms between sub-populations within the prevalent patient population (p>0.05). 
Feasibility
Six children (5 %) had missing scores for at least one of the PROMIS domains and two (2 
%) children had missing scores in the PedsQL. Sixteen children (13 %) skipped one or more 
PROMIS questions, and ten children (8 %) skipped one or more PedsQL questions. A 
missing value analysis showed that there was no pattern to the domains/questions missed by 
disease duration, age, sex, or race. Overall, the frequencies across the two instruments 
looked similar and missing scores were infrequent (the highest level of missingness was 3 
for 3 items in PedsQL and 2 items in PROMIS).
PROMIS
Table 3 shows the unadjusted mean scores for the PROMIS and PedsQL measures in 
children with incident and prevalent NS at the enrollment visit. The PROMIS scores were 
significantly worse in prevalent patients compared to incident patients in the domains of 
pain interference (p < 0.01) and peer relationships (p=0.01). On multivariable analysis 
(Table 4) children with prevalent NS had on average a PROMIS pain interference score 
which was 5 points worse [standard error (SE) 2.0] than that of the incident patients (p= 
0.02).
PedsQL
The PedsQL unadjusted scores were worse in children with prevalent versus incident NS for 
the social functioning (<0.01) and school functioning (p=0.03) measures. On multivariable 
modeling, the score for social functioning was about 10 points worse (SE 3.2) for children 
with prevalent NS versus those with incident NS.
Table 5 shows the scores for the PedsQL domains compared to the previously published 
normative data [18]. The entire patient population and patients with prevalent NS had 
significantly lower scores in all domains on the PedsQL when compared to the normative 
population. Incident patients had significantly lower scores in physical functioning, school 
functioning, and overall HRQOL than the normative patient population.
Disease characteristics impacting HRQOL
Multivariable modeling described several disease characteristics that adversely impact 
HRQOL (Table 4). The number of symptoms predicted worse scores for the PROMIS 
fatigue domain and the PedsQL school functioning measure. The number of medications 
predicted worse scores in the PROMIS peer relationships domain, the PedsQL overall 
HRQOL measure, and the PedsQL school functioning measure. Furthermore, higher levels 
of proteinuria predicted worse scores in the PROMIS mobility domain and PedsQL physical 
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functioning measure. Sensitivity analyses on patients with prevalent disease showed no 
difference in HRQOL by steroid response pattern in the univariate and multivariate analysis.
Simultaneous regression analysis showed that disease duration, edema, number of 
medications, UPC ratio and, to a lesser extent, sex and race were important predictors of 
overall PedsQL scores. An analogous analysis on the PROMIS domains revealed that 
number of medications, eGFR, and UPC ratios were strong predictors of HRQOL.
Comparison of PROMIS and PedsQL
Table 6 shows the results of the analysis of correlation among the PROMIS domains and the 
PedsQL measures. In evaluating similar domains there were strong correlations (correlation 
coefficient>0.5) between PROMIS mobility and PedsQL physical functioning, between 
PROMIS pain interference and PedsQL physical functioning, between PROMIS fatigue and 
PedsQL physical functioning, between PROMIS depression and PedsQL emotional 
functioning, and between PROMIS anxiety and PedsQL emotional functioning. There were 
moderate correlations (0.5≥ correlation coefficient>0.3) between PROMIS peer 
relationships and PedsQL social functioning and between PROMIS peer relationships and 
PedsQL school functioning.
Discussion
This report represents the largest and most comprehensive study to date evaluating HRQOL 
in school age children with active NS. We demonstrate that the PROMIS measures were 
able to detect a negative impact of disease duration on the HRQOL in children with active 
NS, showing that children with prevalent disease have a significantly worse HRQOL than 
those with incident disease. These findings were confirmed by the PedsQL measures. We 
also show that the HRQOL in this sample, as measured by the PedsQL, was impaired when 
compared to general pediatric (normative) populations. Furthermore, we demonstrate that 
the PedsQL and PROMIS instruments perform similarly, but with important differences.
In children with chronic illnesses, the focus of research and clinical assessment is frequently 
the impact of disease activity. The burden on HRQOL may be reflective not only of the 
current state of disease activity and treatment, but also of the cumulative psychosocial 
impact of the disease course, duration, and cumulative medication exposure. This may be 
particularly true with a disease process like NS that is unpredictable—showing a relapsing 
and remitting nature or manifesting as persistent and progressive disease requiring ongoing 
management, including medications, dietary restrictions, and laboratory assessments. In the 
adult literature, a recent study has demonstrated the negative impact of disease duration in 
NS on HRQOL [20]. By comparing children with incident NS to those with prevalent NS, 
we focused on evaluating the contribution of disease duration to HRQOL in pediatric NS. 
Our study is the first to demonstrate that disease duration negatively impacts HRQOL in 
children with active NS. Specifically, the bivariate analysis showed that PROMIS peer 
relationships and pain interference scores were worse in children with prevalent NS than in 
those with incident diseases. On multivariable analysis, prevalent disease continued to 
predict a worse score in the PROMIS pain interference domain. These findings show the 
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impact of disease duration on HRQOL and the ability of the PROMIS measures to detect 
this in children with active NS.
The impact of disease duration on HRQOL in children with active NS was confirmed by the 
concurrent findings of the legacy instrument (PedsQL). Specifically, on bivariate analysis, 
the PedsQL social and school functioning scores for the children with active NS were worse 
in those with prevalent NS than in those with incident NS. In multivariable analysis, 
prevalent disease continued to predict worse scores in PedsQL social functioning. One might 
postulate that the poorer HRQOL in the school and social functioning domains reported by 
patients with prevalent NS may in part reflect cumulative school absences. Unfortunately, 
this study did not capture school absences. The findings of poor HRQOL on the pain 
interference and psychosocial domains in the PROMIS and PedsQL may provide 
opportunities to measure and address the impact of disease and disease duration during 
clinical encounters.
The impact of NS on HRQOL in children has been reported in a number of studies [2–4]. 
An important limitation of the PROMIS measures are that there is currently no reference 
data on scores in a healthy pediatric patient population, but research evaluating this is 
currently ongoing. As a result, the PedsQL was utilized to compare the HRQOL in children 
with active NS to healthy general pediatric patients. The HRQOL within this sample was 
impaired when compared to general healthy pediatric (normative) populations as measured 
by the PedsQL (Table 5) [18]. This impairment was present in all domains in the entire 
study cohort, further demonstrating the pervasive impairments in HRQOL in the broadest 
pediatric NS patient population reported to date. Furthermore, the patterns of impairment 
were more impressive when the prevalent patient population was compared separately to the 
control population, with prevalent patients having significant burdens in all domains. 
Interestingly, children with incident NS did not demonstrate a significantly different 
HRQOL in the domains of emotional and social functioning when compared to healthy 
children, indicating that children with new onset disease continue to maintain pre-disease 
emotional and social functioning.
In evaluating the current study, it is of value to compare the current population to the 
previously published PROMIS I NS cohort [3]. An interesting finding in comparing the 
domain scores between the PROMIS I cohort and the current PROMIS II cohort, is that 
there were worse scores in four of the six domains in the present study. This likely reflects 
fundamental differences between the studies and the patient populations. In the present 
study, eligibility was dependent on the presence of active NS with proteinuria at the time of 
the initial assessment. In addition, the patient cohort of the present study had a higher rate of 
obesity and hospitalization in the 6 months prior to initial assessment than the PROMIS I 
sample. We have previously shown each of these factors to strongly impact HRQOL [3, 12]. 
Another potential and simpler explanation is that disease duration at enrollment was not 
measured in the PROMIS I cohort and that the differences seen may reflect this contribution 
of this factor. In PROMIS I we showed the impact of active edema on HRQOL in children 
with NS. Children with active edema demonstrated worse anxiety, pain interference, fatigue, 
and mobility scores compared to those without edema. Interestingly, in our current study, 
which includes only patients with significant proteinuria as an objective measure of disease 
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activity, edema does not parlay the same increased burden on HRQOL. The most obvious 
explanation for this would be that every participant in this PROMIS II study was required to 
have active NS (high-grade protein-uria, with or without edema). In aggregate, we postulate 
that the impact of NS on HRQOL is more complicated than simply the impairments 
associated with edema, rather they also reflect the impact of additional characteristics, such 
as disease duration, medication burden, number of relapses, among others.
PROMIS and PedsQL provide complementary HRQOL information on children’s HRQOL. 
The addition of PROMIS to the HRQOL assessment armamentarium provides the clinician 
and researcher with a tool that is potentially more expansive, flexible, and precise. As part of 
the validation of PROMIS, it is important to compare PROMIS with the PedsQL measure in 
the same patient population. While the instruments were developed utilizing different 
methodologies, we hypothesized that they would show similar, but not identical findings for 
domains in common on the measures. To date, there has not been a study simultaneously 
describing the findings of the PedsQL and PROMIS measures in children with NS. We show 
that there is a correlation between the scores in similar domains in these measures (Table 6). 
The majority of domains we tested showed a strong correlation, with the strongest ones 
existing between the PedsQL emotional functioning domain and the PROMIS domains of 
depression and anxiety, as expected. The weakest correlation was found between the social 
function and school functioning domains of the PedsQL instrument and the peer 
relationships domain of the PROMIS instrument. We have shown that children 
demonstrated an increased burden of symptoms in similar domains for the PedsQL and the 
PROMIS instrument, but there remain important differences in the measures of the 
instruments that likely reflect their different methods of development.
The current study is limited by its cross-sectional nature. The longitudinal follow-up of this 
cohort is ongoing. The PROMIS pediatric measures are limited to children of ages 8–17 
years, which likely explains the age distribution of the study participants. At the time of this 
study, only an English version and a school age self-report version of the PROMIS pediatric 
instrument were available. Consequently, the results of this study will be most applicable to 
English-speaking, school age children. Another limitation of the current study is that there 
were seven patients with unknown or incomplete steroid-response/disease status. Finally, 
this study does not address the potential distinct contributions of disease status and 
medication effects on pediatric HRQOL. Future studies will provide opportunities to address 
these important issues.
Conclusions
This study demonstrates that the duration of NS directly impacts several aspects of HRQOL. 
Children with prevalent disease reported poorer HRQOL in the domains of PROMIS peer 
relationships, PROMIS pain interference, PedsQL social functioning, and PedsQL school 
functioning scores when compared to children with incident disease. Furthermore, this study 
shows that the PROMIS and the PedsQL measures provide complementary results but that 
there remain important differences in the measures of the instruments that likely reflect their 
different content coverage.
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The next steps in this investigation will be to evaluate the longitudinal responsiveness of the 
PROMIS measures to the change in disease status in children with NS and to develop and 
test interventions to specifically address the negative HRQOL impact of NS on children.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Demographics of the pediatric patients enrolled in the study






 8–12 67 (53) 23 (38) 44 (66) <0.01
 13–17 60 (47) 37 (62) 23 (34)
Male 83 (65) 36 (60) 47 (70) 0.23
Race (N = 126)
 White 65 (52) 26 (44) 39 (59) 0.02
 Black 36 (29) 18 (30) 18 (27)
 Asian 16 (13) 13 (22) 3 (5)
 Other 9 (7) 3 (5) 6 (9)
Obese (N = 126) 44 (35) 18 (30) 26 (39) 0.30
Edema present 96 (76) 53 (88) 43 (64) <0.01
Hypertension (N = 126) 53 (42) 25 (42) 28 (42) 0.93
Steroid treatment (N = 123) 73 (59) 19 (32) 54 (84) <0.01
Number of symptoms 3 (2,6) 3 (1,5) 4 (2,6) 0.04
Emergency department visits (≥1 visit) (N = 124) 49 (40) 27 (46) 22 (34) 0.18
Hospitalizations within the last 6 months (N = 125) 57 (46) 34 (57) 23 (35) 0.02
Estimated GFR (mL/min/1.73 m2) (N = 126) 111.3 (81.5, 133.7) 105.5 (76.9, 128.9) 115.0 (92.8, 142.9) 0.09
Urine protein:creatinine ratio (N = 110) 5.4 (2.3, 8.7) 6.6 (4.5, 9.6) 3.5 (1.7, 6.8) <0.01
Albumin (N = 126) 2.3 (1.6,3.1) 1.9 (1.6, 2.7) 2.7 (1.7, 3.5) <0.01
Months of steroid exposureb 23 (1, 51) 0 (0, 0.5) 25 (11, 58) <0.01
Number of medications 2 (1, 4) 2 (1, 3) 3 (1, 6) 0.01
NS, Nephrotic syndrome; GFR, glomerular filtration rate
Data are reported as the number with the percentage (%) in parenthesis, or as the median with the interquartile range (IQR) in parenthesis 
(continuous variables), as appropriate
a
Incident patients: children at their initial presentation and with <14 days of therapy before enrollment; prevalent patients: all other patients who 
were not incident patients
b
Calculated from the 73 patients receiving steroid therapy at the visit (19 incident and 54 prevalent patients)
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Table 2
Symptom burden during the previous 7 days
Symptoms All patients Patients with incident NS Patients with prevalent NS p
Acne 17 (13) 9 (15) 8 (12) 0.61
Behavioral changes 14 (11) 5 (8) 9 (13) 0.36
Mood 27 (21) 8 (13) 19 (28) 0.04
Cough 33 (26) 13 (22) 20 (30) 0.29
Swelling 47 (37) 19 (32) 28 (42) 0.24
Hunger 24 (19) 9 (15) 15 (22) 0.29
Insomnia 19 (15) 9 (15) 10 (15) 0.99
Stomach pain 43 (34) 17 (28) 26 (39) 0.21
Shortness of breath 13 (10) 9 (15) 4 (6) 0.09
Diarrhea 27 (21) 10 (17) 17 (25) 0.23
Nausea/vomiting 25 (20) 10 (17) 15 (22) 0.42
Weight gain 54 (43) 27 (45) 27 (40) 0.59
Total number of symptoms per patient 3 (2, 6) 3 (1, 5) 4 (2, 6) 0.04
Data for individual symptoms are reported as the number with the percentage (%) in parenthesis; data on total number of symptoms are presented 
as the median with the IQR in parenthesis
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Table 3
Comparison of health-related quality of life in children with incident and prevalent nephrotic syndrome
Instrument domains All Patients with incident NS Patients with prevalent NS p
PROMIS
 Mobility 46.3±9.2 46.5±10.3 46.1±8.3 0.85
 Depression 49.7±9.3 48.4±9.1 50.8±9.5 0.15
 Anxiety 49.4±10.6 48.9±10.9 49.9±10.4 0.63
 Fatigue 49.6±12.6 49.0±13.1 50.2±12.2 0.59
 Peer relationships 48.6±10.6 51.2±10.2 46.4±10.6 0.01
 Pain interference 49.7±11.1 46.6±11.3 52.3±10.3 <0.01
PedsQL
 Physical functioning 69.3±22.7 68.8±25.7 69.8±19.9 0.81
 Emotional functioning 72.3±22.1 75.6±21.5 69.2±22.3 0.10
 Social functioning 80.6±18.0 86.4±14.4 75.2±19.3 <0.01
 School functioning 62.5±21.7 66.9±20.3 58.5±22.3 0.03
 Overall HRQOL 71.0±17.0 73.7±17.8 68.6±16.0 0.09
PROMIS, Patient Reported Outcomes Measurement Information System®; PedsQL; PedsQL™ 4.0 Generic Core Scales Data presented as the 
mean±standard deviation (SD)
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Table 4
Linear regression model
HRQOL assessment tools and domains/ variables β (SE) |d| p
Patient reported outcomes measurement information system (PROMIS)
 Mobility
  Prevalent patients −1.6 (1.8) 0.17 0.39
  UPC ratio −0.3 (0.1) 0.01
 Depression
  Prevalent patients 2.4 (1.7) 0.26 0.16
 Anxiety
  Prevalent patients 0.9 (1.9) 0.10 0.63
 Fatigue
  Prevalent patients 0.6 (2.3) 0.02 0.80
  Symptom number 0.9 (0.4) 0.05
 Peer relationships
  Prevalent patients −2.7 (2.0) 0.25 0.18
  Age 0.8 (0.3) 0.02
  Number of medications −0.8 (0.4) 0.04
 Pain interference
  Prevalent patients 4.7 (2.0) 0.42 0.02
  Number of medications 0.7 (0.4) 0.07
PedsQL™ 4.0 Generic Core Scales (PedsQL)
 Physical functioning
  Prevalent patients −1.0 (4.4) 0.04 0.83
  Urine protein: creatinine −0.8 (0.3) 0.01
 Emotional functioning
  Prevalent patients −5.9 (4.1) 0.27 0.15
  Number of medications −0.4 (0.8) 0.61
 Social functioning
  Prevalent patients −9.7 (3.2) 0.54 <0.01
  Number of medications −1.1 (0.6) 0.07
 School functioning
  Prevalent patients −4.2 (3.7) 0.19 0.26
  Symptom number −2.4 (0.7) <0.01
  Number of medications −1.9 (0.7) <0.01
 Overall HRQOL
  Prevalent patients −3.5 (3.1) 0.21 0.25
  Number of medications −1.2 (0.6) 0.05
SE, Standard error; HRQOL, health-related quality of life; BMI, body mass index; |d|, effect size
The following variables were considered in each model: sex, age, race, Hispanic ethnicity, obesity (BMI>95th percentile), hypertension, edema, 
number of symptoms, estimated (e)GFR, UPC ratio, serum albumin, hospitalization in the past 6 months, emergency room visit in the past 6 
months, number of medications, steroid exposure, and disease duration coded as incident vs. prevalent
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The following variables had no effect on HRQOL: gender, race, ethnicity, weight status, edema, hypertension, steroid treatment, hospital or 
emergency room visits in the past 6 months, height percentile, eGFR, albumin, and hemoglobin
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